365213-69-0

Basic information

• Product Name: (2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID
• Synonyms: (2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID;2-(2-p-tolylH-iMidazo[1,2-a]pyridin-3-yl)acetic acid
• CAS NO: 365213-69-0
• Molecular Formula: C₁₆H₁₄N₂O₂
• Molecular Weight: 266.29
• Mol File: 365213-69-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID(365213-69-0)
• EPA Substance Registry System: (2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID(365213-69-0)

Safety Data

• Hazardous Substances Data: 365213-69-0(Hazardous Substances Data)

Usage

General Description

"(2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID" is a chemical compound with the molecular formula C16H14N2O2. It is an imidazopyridine derivative, a class of chemical compounds that have potential pharmacological properties. This specific compound has been studied for its potential as a drug candidate for various medical conditions, including neurological and psychiatric disorders. It is a synthesized compound and is not naturally occurring in the environment. The precise mechanism of action and potential uses for this compound are still under investigation, but it shows promise as a potential drug candidate for future medical treatments.

Upstream product

• 365213-61-2 2-(2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide 
• 65964-60-5 2-para-tolylimidazo[1,2-a]pyridine 
• 365213-41-8 N,N-dimethyl-1-(2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)methanamine 
• 122-00-9 para-methylacetophenone 
• 124658-44-2 C₁₃H₁₄O₃ 
• 504-29-0 2-aminopyridine 
• 16208-14-3 2,2-dihydroxy-1-(p-tolyl)ethanone 

Relevant articles and documents

Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3)

STAT3 has been validated as an attractive anticancer target due to its important roles in cancer initiation and progression. However, discovery of potent and selective STAT3 small-molecule inhibitors with druglike properties is still challenging. In this study, two series of substituted 2-phenylquinolines and 2-arylimidazo[1,2-a]pyridines were designed through structure-based drug discovery approach by condensing the privileged structures of STX-119 and SH4-54. Our study has resulted in the discovery of a number of highly potent and selective STAT3 inhibitors, exemplified by compound 39 with the privileged structure of 2-phenylimidazo[1,2-a]pyridine, which selectively inhibits phosphorylation of STAT3 and suppresses subsequent signaling pathway. Moreover, 39 inhibits cell growth, migration and invasion of human triple negative breast cancer (TNBC) cells lines. Consistently, it achieves significant and dose-dependent tumor growth inhibition in both cell line-derived and patient-derived xenograft tumor models in mice. These results clearly indicate that 39 is a highly potent and selective STAT3 inhibitor.

Synthesis of Substituted Imidazo[1,2-a]Pyridin-3-yl-Acetic Acids by Multicomponent Condensation of 2-Aminopyridines with Arylglyoxals and Meldrum’s Acid

[Figure not available: see fulltext.] A simple and effective method for the synthesis of substituted imidazo[1,2-a]pyridin-3-yl-acetic acids has been developed based on the multicomponent condensation of 2-aminopyridines with arylglyoxals and Meldrum's acid.

A structure-activity relationship study of the affinity of selected imidazo[1,2-a]pyridine derivatives, congeners of zolpidem, for the ω1-subtype of the benzodiazepine receptor

A series of 6-substituted 2-aryl-N,N-dimethylimidazol [1,2-a]pyridine-3-acetamides, congeners of zolpidem and alpidem, was synthesized and tested in vitro for binding with the benzodiazepine receptor in the competition with 3H-zolpidem as an ω1-selective radioligand. Molecular electrostatic potential (MEP) and the HOMO and LUMO energies were calculated for the compounds by semi-empirical quantum chemistry methods. The lipophilicity parameter of the compounds, expressed as the logarithm of the octanol-water partition coefficient (log P), was calculated; alternatively, standard values of the Hansch hydrophobic substituent constants π were used. In agreement with earlier investigations on the benzodiazepine receptor ligands with a high preference for the ω1-subtype, a quantitative correlation of the biological data with molecular parameters has revealed a significant dependence (r=0.954) of the binding affinity (IC50) on the deepest MEP minimum, in this case associated with the amide carbonyl oxygen atom. The lipophilicity parameters were found to be of lower significance.